Home › Glioma › Massachusetts › Boston
Glioma clinical trials in Boston, MA
20 studies for Glioma are looking for participants at sites in and around Boston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
MCT for the Harvard/UCSF ROBIN Center
Recruiting
- Brigham and Women's Hospital, Boston
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
RecruitingPhase 1/2
- Dana-Farber Cancer Institute, Boston
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RecruitingPhase 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
RecruitingPhase 1/2
- Dana Farber Cancer Institute., Boston
Targeted Pediatric High-Grade Glioma Therapy
RecruitingObservational study
- Dana-Farber Cancer Institute, Boston
Study of Olutasidenib and Temozolomide in HGG
RecruitingPhase 2
- Susan Chi, Boston
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
RecruitingPhase 3
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
RecruitingPhase 2
- Dana-Farber Cancer Institute, Boston
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
RecruitingPhase 1/2
- Research Site, Boston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RecruitingPhase 2
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
CARv3-TEAM-E T Cells in Glioblastoma
RecruitingPhase 1
- Massachusetts General Hospital Cancer Center, Boston
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RecruitingEarly phase 1Healthy volunteers welcome
- Dana-Farber Cancer Institute, Boston
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RecruitingPhase 2
- Dana-Farber Cancer Institute, Boston
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RecruitingPhase 1/2
- Dana Farber Cancer Institute, Boston
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
RecruitingEarly phase 1
- Dana-Farber Cancer Institute, Boston
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
RecruitingPhase 1
- Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston
CUE-102 in Recurrent Glioblastoma
RecruitingPhase 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
NeuroPathways Intervention for Brain Tumor Patients
Recruiting
- Massachusetts General Hospital Cancer Center, Boston
ASCENT Intervention for Brain Tumor Patients
Recruiting
- Massachusetts General Hospital Cancer Center, Boston
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
RecruitingObservational study
- Massachusetts General Hospital, Boston
Glioma trials in other cities
- New York City, NY25 studies
- Houston, TX23 studies
- Washington, DC19 studies
- Philadelphia, PA16 studies
- Miami, FL15 studies
- Columbus, OH15 studies
- San Francisco, CA14 studies
- Chicago, IL13 studies
- Durham, NC12 studies
- Seattle, WA11 studies
- St. Louis, MO10 studies
- Los Angeles, CA10 studies
Other studies in Boston
- Breast Cancer111 studies
- Non-Small Cell Lung Cancer90 studies
- Cancer (all types)86 studies
- Colorectal Cancer63 studies
- Metastatic Cancer63 studies
- Lung Cancer62 studies
- Ovarian Cancer61 studies
- Prostate Cancer59 studies
- Depression52 studies
- Endometrial Cancer50 studies
- Heart Failure44 studies
- Acute Myeloid Leukemia44 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.